In short-term trials chlorophenoxyisobutyric acid (CPIB) (Atromid-S) reduced the plasma cholesterol and triglyceride levels in eight subjects with type II and IV hyperlipidemias to an equal extent. In these subjects, who were maintained on constant solid food diets, CPIB administration resulted in increased excretion of fecal neutral and acidic sterols in the type II subjects only. There was an immediate increase in specific activity of plasma cholesterol in seven of the eight subjects, and a reduced rate of fall of specific activity in many of the subjects. It is suggested that CPIB inhibits the synthesis of cholesterol in vivo, and that the subsequent fall in plasma cholesterol is responsible for the release of cholesterol with higher specific activity from tissues into the plasma pool.
Plasma triglycerides
Specific activity Inhibition of synthesis CHLOROPHENOXYISOBUTYRIC acid (CPIB) has been found to be an effective drug in the treatment of hyperlipidemias characterized by increases in cholesterol and triglycerides (type IV of Frederickson's classification), and of limited value in the treatment of hypercholesterolemia without elevated triglycerides (type II).1 Its November 4, 1970. Circulation, Volume XLIII, February 1971 synthesis of cholesterol with reduced dilution of the labeled pool. Recently Grundy et al. 4 reported that, in hyperlipidemic patients, the drug caused an increase in excretion of cholesterol and its metabolites in the feces.
We wish to report on the effect of shortterm treatment with CPIB on cholesterol metabolism in individuals with type II and type IV hyperlipidemia.
Methods
We studied subjects with hyperlipidemia and/or coronary heart disease ( The total amount of radioactivity in the fecal neutral and acidic fractions was divided by the SA of plasma cholesterol at the start of the collection period in order that the mass of neutral and acidic sterols arising from the plasma cholesterol pool might be obtained. The results obtained were corrected for stool flow and losses by determination of the chromic oxide content per gram of fecal emulsion.13 neutral sterols (mg/day) _ total radioactivity in neutral steroid fraction (dpm/day) SA of plasma cholesterol (dpm/mg) 2 days previously Daily excretion of endogenous fecal acidic sterols (mg/day) _ total radioactivity in acidic steroid fraction (dpm/day) SA of plasma cholesterol (dpm/mg) 2 ment of the losses of sitosterols, which are poorly absorbed in their passage through the gastrointestinal tract. The results for fecal neutral sterols given in this paper are not corrected for degradation, and may represent an underestimate of the total fecal neutral sterols excreted. Denbesten et al. 15 have reported that sterol degradation is specific to formula diets lacking cellulose, and does not occur when natural food diets are fed. Since our subjects all received natural food diets, it is unlikely that any sterol degradation occurred.
Results

Plasma Lipids
Treatment with CPIB resulted in prompt and consistent reduction in plasma cholesterol and triglyceride levels in all subjects ( fig. 1) . The fall was apparent in the first blood samples drawn 2 to 5 days after treatment was begun, and the levels stabilized at 15 to 20 days of treatment. The reduction in serum lipids during the treatment period was essenCirculation, Volume XLIlI, February 1971 tially similar in both types II and IV, and is shown in table 3. The effects of stoppage of treatment with CPIB were studied in one type II subject (F.G.) and in two type IV subjects (T.R. and P.P.). In all three, the cholesterol remained low during the period of observation (12-15 days), whereas the triglycerides promptly returned to pretreatment levels. Later measurements showed a slow return of cholesterol to pretreatment levels. The addition of a low calorie diet to CPIB treatment in one type IV subject (A.M.) resulted in a further fall in plasma cholesterol and triglycerides. One subject in the type IV group (P.P.), whose pretreatment triglyceride levels ranged between 729 and 209 mg/ 100 ml over a 1-year period, showed a fall in his triglyceride levels when placed on the, equicaloric constant diet (dietary equilibration period). This decrease was apparently due to a slight weight loss resulting from an underes- The three type II subjects and the single subject with normal lipids showed a consistent increase in the excretion of fecal neutral sterols during the treatment period. Three out of four also showed an increased excretion of acidic sterols. In one subject (F.G.), cessation of treatment resulted in a prompt return to pretreatment levels. Type The curves of SA of plasma cholesterol became exponential 3 to 4 weeks after injection of 14C-cholesterol, and before the control studies were begun. In order to be certain that these changes in the curve of SA of plasma cholesterol were not an artifact due to the rather unphysiological method of administering the 14C-cholesterol, we administered a separate dose of 3H-cholesterol orally to a subject (L.H.) who had already received 14C-cholesterol intravenously. The curves of SA of plasma cholesterol (14C and 3H) both showed the initial rise in SA (fig. 4) .
Discussion
These results relate to relatively short-term effects of CPIB treatment. During the brief treatment period (12) (13) (14) (15) days) there were significant reductions in plasma lipids in both types II and IV subjects. Short-term reductions in plasma lipids in types II and IV subjects treated with CPIB have been reported by many observers,16 17 Figure 7 orders, and that they might respond differently to the drug. Thus the diabetic diathesis is rare in type II, but common in type IV patients. The type IV patient is very sensitive to weight restriction and, to a lesser degree, to restriction Our results suggest that in the type II subject CPIB has two independent effects: (1) it appears to inhibit synthesis of cholesterol (as evidenced by the reduction of plasma cholesterol levels and flattening of the plasma SA curve), and (2) it increases the excretion of fecal neutral sterols and bile acids. In the type IV subject our data suggest inhibition of synthesis of cholesterol (reduction in plasma levels and in slope of SA curve of plasma cholesterol), but no effect on the excretion of neutral or acidic sterols.
